Reuters
18 Aug 2026, 07:04 UTC · 2h ago
LEO Pharma buys worldwide dersimelagon rights for up to $435 million
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
18 Aug 2026, 07:04 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
LEO Pharma agreed to acquire worldwide rights to the drug candidate dersimelagon from Tanabe Pharma. — Expansion of the pipeline through acquisition typically increases the long-term valuation of the acquiring firm if the candidate is successful.
+0.30The acquisition deal involves up-front and near-term milestone payments of up to $435 million. — The cash outlay is a material expenditure but represents a standard investment for pharmaceutical drug rights.
+0.10Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Continue reading
6 related stories
Top 1 mover · tap to explore
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
18h ago
